• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For February 28, 2022

    2/28/22 4:17:09 AM ET
    $AAON
    $ACAD
    $ACHC
    $AGM
    Industrial Machinery/Components
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AAON alert in real time by email

     

    Companies Reporting Before The Bell

    • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.

    • Praxis Precision Medicine (NASDAQ:PRAX) is likely to report earnings for its fourth quarter.

    • Blackstone Secured (NYSE:BXSL) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million.

    • Mersana Therapeutics (NASDAQ:MRSN) is estimated to report earnings for its fourth quarter.

    • Partner Communications Co (NASDAQ:PTNR) is expected to report earnings for its fourth quarter.

    • Daqo New Energy (NYSE:DQ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million.

    • Easterly Government Props (NYSE:DEA) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million.

    • Aurinia Pharmaceuticals (NASDAQ:AUPH) is expected to report earnings for its fourth quarter.

    • Kosmos Energy (NYSE:KOS) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.81 million.

    • Verso (NYSE:VRS) is estimated to report quarterly earnings at $0.66 per share on revenue of $298.41 million.

    • Tegna (NYSE:TGNA) is likely to report quarterly earnings at $0.55 per share on revenue of $772.59 million.

    • FREYR Battery (NYSE:FREY) is expected to report earnings for its fourth quarter.

    • Cano Health (NYSE:CANO) is estimated to report quarterly loss at $0.02 per share on revenue of $531.65 million.

    • Butterfly Network (NYSE:BFLY) is projected to report quarterly loss at $0.26 per share on revenue of $17.00 million.

    • Lordstown Motors (NASDAQ:RIDE) is estimated to report earnings for its fourth quarter.

    • XPEL (NASDAQ:XPEL) is projected to report quarterly earnings at $0.30 per share on revenue of $69.21 million.

    • Viatris (NASDAQ:VTRS) is projected to report quarterly earnings at $0.83 per share on revenue of $4.35 billion.

    • Global Partners (NYSE:GLP) is expected to report quarterly earnings at $0.23 per share on revenue of $3.99 billion.

    • National Vision Holdings (NASDAQ:EYE) is estimated to report quarterly loss at $0.02 per share on revenue of $459.56 million.

    • Reata Pharmaceuticals (NASDAQ:RETA) is likely to report quarterly loss at $2.31 per share on revenue of $1.63 million.

    • HNI (NYSE:HNI) is estimated to report quarterly earnings at $0.41 per share on revenue of $596.63 million.

    • Fomento Economico (NYSE:FMX) is likely to report quarterly earnings at $1.11 per share on revenue of $6.99 billion.

    • Alcon (NYSE:ALC) is estimated to report quarterly earnings at $0.62 per share on revenue of $170.00 million.

    • Cactus (NYSE:WHD) is projected to report quarterly earnings at $0.20 per share on revenue of $123.26 million.

    • Itron (NASDAQ:ITRI) is expected to report quarterly earnings at $0.19 per share on revenue of $505.76 million.

    • Heska (NASDAQ:HSKA) is estimated to report quarterly loss at $0.04 per share on revenue of $65.62 million.

    • VEON (NASDAQ:VEON) is expected to report quarterly earnings at $0.08 per share on revenue of $2.01 billion.

    • Dentsply Sirona (NASDAQ:XRAY) is estimated to report quarterly earnings at $0.79 per share on revenue of $1.13 billion.

    • Astec Industries (NASDAQ:ASTE) is likely to report quarterly earnings at $0.02 per share on revenue of $267.89 million.

    • Civeo (NYSE:CVEO) is expected to report earnings for its fourth quarter.

    • Nielsen Holdings (NYSE:NLSN) is estimated to report quarterly earnings at $0.35 per share on revenue of $898.13 million.

    • Party City Holdco (NYSE:PRTY) is projected to report quarterly earnings at $0.40 per share on revenue of $697.25 million.

    • Jones Lang LaSalle (NYSE:JLL) is likely to report quarterly earnings at $6.81 per share on revenue of $2.56 billion.

    • Clearway Energy (NYSE:CWEN) is expected to report earnings for its fourth quarter.

    • Enel Chile (NYSE:ENIC) is expected to report earnings for its fourth quarter.

    • Itau Corpbanca (NYSE:ITCB) is projected to report earnings for its fourth quarter.

     

    Companies Reporting After The Bell

    • Asensus Surgical (AMEX:ASXC) is estimated to report quarterly loss at $0.07 per share on revenue of $1.51 million.

    • Ocular Therapeutix (NASDAQ:OCUL) is estimated to report quarterly loss at $0.23 per share on revenue of $14.44 million.

    • Atea Pharmaceuticals (NASDAQ:AVIR) is expected to report quarterly earnings at $0.17 per share on revenue of $85.73 million.

    • Lucid Gr (NASDAQ:LCID) is estimated to report quarterly loss at $0.35 per share on revenue of $36.74 million.

    • Revolution Medicines (NASDAQ:RVMD) is expected to report quarterly loss at $0.64 per share on revenue of $8.92 million.

    • Supernus Pharmaceuticals (NASDAQ:SUPN) is estimated to report quarterly earnings at $0.24 per share on revenue of $149.42 million.

    • Heron Therapeutics (NASDAQ:HRTX) is projected to report quarterly loss at $0.58 per share on revenue of $25.59 million.

    • Pennant Group (NASDAQ:PNTG) is expected to report quarterly earnings at $0.15 per share on revenue of $109.74 million.

    • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.04 per share on revenue of $269.80 million.

    • UserTesting (NYSE:USER) is expected to report quarterly loss at $0.18 per share on revenue of $39.01 million.

    • Revance Therapeutics (NASDAQ:RVNC) is likely to report quarterly loss at $1.02 per share on revenue of $24.27 million.

    • Preferred Apartment (NYSE:APTS) is projected to report quarterly loss at $0.65 per share on revenue of $102.02 million.

    • Apellis Pharmaceuticals (NASDAQ:APLS) is likely to report quarterly loss at $1.54 per share on revenue of $8.78 million.

    • Ardelyx (NASDAQ:ARDX) is estimated to report quarterly loss at $0.30 per share on revenue of $700.00 thousand.

    • Sterling Construction Co (NASDAQ:STRL) is projected to report quarterly earnings at $0.37 per share on revenue of $337.60 million.

    • Darling Ingredients (NYSE:DAR) is projected to report quarterly earnings at $0.88 per share on revenue of $1.22 billion.

    • Shenandoah (NASDAQ:SHEN) is likely to report quarterly earnings at $0.04 per share on revenue of $62.92 million.

    • Commercial Vehicle Group (NASDAQ:CVGI) is expected to report quarterly earnings at $0.17 per share on revenue of $221.75 million.

    • Global Cord Blood (NYSE:CO) is projected to report earnings for its third quarter.

    • Novavax (NASDAQ:NVAX) is estimated to report quarterly loss at $1.80 per share on revenue of $331.79 million.

    • Kyndryl Hldgs (NYSE:KD) is projected to report quarterly loss at $0.47 per share on revenue of $4.54 billion.

    • Aris Water Solutions (NYSE:ARIS) is projected to report quarterly earnings at $0.14 per share on revenue of $64.69 million.

    • Rocket Lab USA (NASDAQ:RKLB) is projected to report quarterly loss at $0.05 per share on revenue of $24.17 million.

    • New Mountain Finance (NASDAQ:NMFC) is estimated to report quarterly earnings at $0.30 per share on revenue of $66.69 million.

    • Nerdy (NYSE:NRDY) is projected to report quarterly loss at $0.09 per share on revenue of $41.64 million.

    • Gulfport Energy (NYSE:GPOR) is estimated to report quarterly earnings at $5.03 per share on revenue of $318.97 million.

    • TaskUs (NASDAQ:TASK) is estimated to report quarterly earnings at $0.33 per share on revenue of $216.01 million.

    • Quantum-Si (NASDAQ:QSI) is projected to report earnings for its fourth quarter.

    • Luminar Technologies (NASDAQ:LAZR) is expected to report quarterly loss at $0.11 per share on revenue of $11.83 million.

    • Radius Global Infr (NASDAQ:RADI) is estimated to report quarterly loss at $0.30 per share on revenue of $29.52 million.

    • SEMrush Hldgs (NYSE:SEMR) is expected to report quarterly loss at $0.04 per share on revenue of $52.12 million.

    • Seer (NASDAQ:SEER) is projected to report quarterly loss at $0.32 per share on revenue of $2.23 million.

    • Celldex Therapeutics (NASDAQ:CLDX) is expected to report quarterly loss at $0.42 per share on revenue of $1.04 million.

    • Vaxcyte (NASDAQ:PCVX) is expected to report earnings for its fourth quarter.

    • Canoo (NASDAQ:GOEV) is projected to report earnings for its fourth quarter.

    • Danimer Scientific (NYSE:DNMR) is likely to report quarterly loss at $0.30 per share on revenue of $17.87 million.

    • Blink Charging (NASDAQ:BLNK) is estimated to report quarterly loss at $0.39 per share on revenue of $5.43 million.

    • Montrose Environmental Gr (NYSE:MEG) is expected to report quarterly loss at $0.06 per share on revenue of $121.98 million.

    • BioLife Solutions (NASDAQ:BLFS) is expected to report quarterly loss at $0.17 per share on revenue of $35.81 million.

    • GoodRx Holdings (NASDAQ:GDRX) is likely to report quarterly earnings at $0.10 per share on revenue of $217.46 million.

    • ON24 (NYSE:ONTF) is likely to report quarterly loss at $0.09 per share on revenue of $51.66 million.

    • comScore (NASDAQ:SCOR) is projected to report quarterly loss at $0.12 per share on revenue of $97.02 million.

    • Surgery Partners (NASDAQ:SGRY) is likely to report quarterly earnings at $0.19 per share on revenue of $621.74 million.

    • Oak Street Health (NYSE:OSH) is estimated to report quarterly loss at $0.57 per share on revenue of $393.53 million.

    • SI-BONE (NASDAQ:SIBN) is projected to report quarterly loss at $0.39 per share on revenue of $24.70 million.

    • MiMedx Group (NASDAQ:MDXG) is estimated to report quarterly loss at $0.03 per share on revenue of $63.69 million.

    • Castle Biosciences (NASDAQ:CSTL) is projected to report quarterly loss at $0.47 per share on revenue of $23.74 million.

    • SmileDirectClub (NASDAQ:SDC) is estimated to report quarterly loss at $0.27 per share on revenue of $127.71 million.

    • Vroom (NASDAQ:VRM) is estimated to report quarterly loss at $0.77 per share on revenue of $901.91 million.

    • Verra Mobility (NASDAQ:VRRM) is expected to report quarterly earnings at $0.22 per share on revenue of $158.34 million.

    • NV5 Global (NASDAQ:NVEE) is likely to report quarterly earnings at $1.04 per share on revenue of $186.32 million.

    • Hanger (NYSE:HNGR) is estimated to report quarterly earnings at $0.44 per share on revenue of $315.45 million.

    • Helios Technologies (NYSE:HLIO) is estimated to report quarterly earnings at $0.83 per share on revenue of $204.80 million.

    • Gaia (NASDAQ:GAIA) is expected to report quarterly earnings at $0.03 per share on revenue of $20.87 million.

    • FS KKR Capital (NYSE:FSK) is expected to report quarterly earnings at $0.61 per share on revenue of $343.37 million.

    • Atara Biotherapeutics (NASDAQ:ATRA) is estimated to report quarterly loss at $0.69 per share on revenue of $35.14 million.

    • FibroGen (NASDAQ:FGEN) is expected to report quarterly loss at $0.66 per share on revenue of $47.65 million.

    • Arcturus Therapeutics (NASDAQ:ARCT) is expected to report quarterly loss at $1.72 per share on revenue of $14.72 million.

    • Mirati Therapeutics (NASDAQ:MRTX) is estimated to report quarterly loss at $3.00 per share on revenue of $1.25 million.

    • Velodyne Lidar (NASDAQ:VLDR) is expected to report quarterly loss at $0.17 per share on revenue of $16.65 million.

    • SailPoint Technologies (NYSE:SAIL) is expected to report quarterly loss at $0.06 per share on revenue of $113.74 million.

    • PRA Group (NASDAQ:PRAA) is likely to report quarterly earnings at $0.66 per share on revenue of $252.55 million.

    • Nelnet (NYSE:NNI) is estimated to report quarterly earnings at $2.23 per share on revenue of $336.25 million.

    • Nektar Therapeutics (NASDAQ:NKTR) is likely to report quarterly loss at $0.81 per share on revenue of $25.33 million.

    • James River Gr Hldgs (NASDAQ:JRVR) is likely to report quarterly earnings at $0.12 per share on revenue of $198.57 million.

    • Dynavax Technologies (NASDAQ:DVAX) is estimated to report quarterly earnings at $0.69 per share on revenue of $208.87 million.

    • Broadmark Realty Capital (NYSE:BRMK) is estimated to report quarterly earnings at $0.21 per share on revenue of $33.95 million.

    • Valens Co (NASDAQ:VLNS) is projected to report quarterly loss at $0.12 per share on revenue of $20.64 million.

    • Progyny (NASDAQ:PGNY) is estimated to report quarterly earnings at $0.04 per share on revenue of $136.08 million.

    • PDC Energy (NASDAQ:PDCE) is likely to report quarterly earnings at $2.55 per share on revenue of $671.52 million.

    • icad (NASDAQ:ICAD) is projected to report quarterly loss at $0.11 per share on revenue of $8.39 million.

    • Fate Therapeutics (NASDAQ:FATE) is likely to report quarterly loss at $0.67 per share on revenue of $10.73 million.

    • Enviva (NYSE:EVA) is projected to report quarterly earnings at $0.26 per share on revenue of $332.02 million.

    • PubMatic (NASDAQ:PUBM) is projected to report quarterly earnings at $0.27 per share on revenue of $75.54 million.

    • Primoris Services (NASDAQ:PRIM) is likely to report quarterly earnings at $0.56 per share on revenue of $892.94 million.

    • Forum Energy Technologies (NYSE:FET) is estimated to report quarterly loss at $0.80 per share on revenue of $150.00 million.

    • Freshpet (NASDAQ:FRPT) is estimated to report quarterly loss at $0.16 per share on revenue of $116.45 million.

    • Centerspace (NYSE:CSR) is likely to report quarterly loss at $0.45 per share on revenue of $53.48 million.

    • BigCommerce Holdings (NASDAQ:BIGC) is expected to report quarterly loss at $0.12 per share on revenue of $61.82 million.

    • Veracyte (NASDAQ:VCYT) is estimated to report quarterly loss at $0.16 per share on revenue of $61.78 million.

    • AVITA Medical (NASDAQ:RCEL) is expected to report quarterly loss at $0.39 per share on revenue of $7.00 million.

    • Otonomy (NASDAQ:OTIC) is likely to report earnings for its fourth quarter.

    • MBIA (NYSE:MBI) is likely to report quarterly loss at $0.44 per share on revenue of $11.00 million.

    • CrossAmerica Partners (NYSE:CAPL) is likely to report quarterly earnings at $0.21 per share on revenue of $732.98 million.

    • AppFolio (NASDAQ:APPF) is estimated to report quarterly loss at $0.02 per share on revenue of $92.53 million.

    • Ameresco (NYSE:AMRC) is projected to report quarterly earnings at $0.42 per share on revenue of $410.13 million.

    • Ambarella (NASDAQ:AMBA) is expected to report quarterly earnings at $0.42 per share on revenue of $90.16 million.

    • Tetra Technologies (NYSE:TTI) is likely to report earnings for its fourth quarter.

    • Howard Hughes (NYSE:HHC) is projected to report quarterly earnings at $1.63 per share on revenue of $123.70 million.

    • Federal Agricultural (NYSE:AGM) is expected to report earnings for its fourth quarter.

    • AAON (NASDAQ:AAON) is estimated to report quarterly earnings at $0.28 per share on revenue of $136.62 million.

    • Stoneridge (NYSE:SRI) is expected to report quarterly loss at $0.24 per share on revenue of $180.03 million.

    • 3D Sys (NYSE:DDD) is likely to report quarterly earnings at $0.04 per share on revenue of $144.18 million.

    • ACADIA Pharmaceuticals (NASDAQ:ACAD) is expected to report quarterly loss at $0.24 per share on revenue of $135.60 million.

    • Trex Co (NYSE:TREX) is estimated to report quarterly earnings at $0.53 per share on revenue of $302.51 million.

    • Heidrick & Struggles Intl (NASDAQ:HSII) is expected to report quarterly earnings at $0.79 per share on revenue of $261.40 million.

    • Zoom Video Communications (NASDAQ:ZM) is expected to report quarterly earnings at $1.05 per share on revenue of $1.05 billion.

    • Groupon (NASDAQ:GRPN) is projected to report quarterly earnings at $0.19 per share on revenue of $223.53 million.

    • Workday (NASDAQ:WDAY) is estimated to report quarterly earnings at $0.71 per share on revenue of $1.36 billion.

    • Endo International (NASDAQ:ENDP) is likely to report quarterly earnings at $0.67 per share on revenue of $731.40 million.

    • Acadia Healthcare Co (NASDAQ:ACHC) is estimated to report quarterly earnings at $0.68 per share on revenue of $588.05 million.

    • SBA Communications (NASDAQ:SBAC) is projected to report quarterly earnings at $0.69 per share on revenue of $591.27 million.

    • ONEOK (NYSE:OKE) is estimated to report quarterly earnings at $0.89 per share on revenue of $4.34 billion.

    • HP (NYSE:HPQ) is expected to report quarterly earnings at $1.02 per share on revenue of $16.52 billion.

    • Hyster-Yale Materials (NYSE:HY) is likely to report quarterly loss at $1.10 per share on revenue of $786.15 million.

    • Semler Scientific (NASDAQ:SMLR) is expected to report earnings for its fourth quarter.

    • Global Medical REIT (NYSE:GMRE) is projected to report earnings for its fourth quarter.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AAON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAON
    $ACAD
    $ACHC
    $AGM

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    2/27/2026$145.00Buy
    UBS
    GoodRx Holdings Inc.
    $GDRX
    2/27/2026Overweight → Neutral
    Analyst
    PubMatic Inc.
    $PUBM
    2/27/2026$10.50Neutral → Buy
    B. Riley Securities
    Alcon Inc.
    $ALC
    2/26/2026$97.00Equal Weight → Overweight
    Wells Fargo
    ONEOK Inc.
    $OKE
    2/25/2026Outperform → Peer Perform
    Wolfe Research
    Workday Inc.
    $WDAY
    2/25/2026$160.00Outperform → In-line
    Evercore ISI
    Workday Inc.
    $WDAY
    2/25/2026$155.00Buy → Hold
    TD Cowen
    Trex Company Inc.
    $TREX
    2/25/2026$53.00Hold → Buy
    Loop Capital
    More analyst ratings

    $AAON
    $ACAD
    $ACHC
    $AGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director George Walter N. bought $49,795 worth of shares (630 units at $79.04), increasing direct ownership by 1% to 47,157 units (SEC Form 4)

    4 - Freshpet, Inc. (0001611647) (Issuer)

    2/26/26 4:07:13 PM ET
    $FRPT
    Packaged Foods
    Consumer Staples

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAON
    $ACAD
    $ACHC
    $AGM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AAON
    $ACAD
    $ACHC
    $AGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Revolution Medicines with a new price target

    UBS resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $145.00

    2/27/26 8:31:41 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GoodRx downgraded by Analyst

    Analyst downgraded GoodRx from Overweight to Neutral

    2/27/26 8:28:37 AM ET
    $GDRX
    EDP Services
    Technology

    PubMatic upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded PubMatic from Neutral to Buy and set a new price target of $10.50

    2/27/26 8:22:43 AM ET
    $PUBM
    Computer Software: Programming Data Processing
    Technology

    $AAON
    $ACAD
    $ACHC
    $AGM
    Leadership Updates

    Live Leadership Updates

    View All

    Stoneridge Announces Appointment of New Independent Director

    NOVI, Mich., Feb. 26, 2026 /PRNewswire/ -- Stoneridge, Inc. (NYSE:SRI) today announced that it will appoint Aron R. English as a member of its Board of Directors, effective March 16, 2026, pursuant to a cooperation agreement entered into with 22NW, LP. Mr. English will also be nominated for election at the Company's 2026 Annual Shareholders Meeting expected to be held in May. Mr. English is the founder and has served as the portfolio manager of 22NW, LP, a Seattle-based value fund specializing in small and microcap investments with a multi-year investment horizon, since 2014. Pr

    2/26/26 5:00:00 PM ET
    $SRI
    Auto Parts:O.E.M.
    Consumer Discretionary

    Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors

    CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) --  DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the "Board"), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior execu

    2/24/26 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Stoneridge Announces President and Chief Executive Officer Retirement and Leadership Succession Plan

    NOVI, Mich., Feb. 23, 2026 /PRNewswire/ -- Stoneridge, Inc. (NYSE:SRI) today announced that Jim Zizelman, president and chief executive officer, is retiring, effective May 20, 2026, following nearly seven years of dedicated service to the Company. The Stoneridge Board of Directors has appointed Natalia Noblet, the current president of Stoneridge Electronics, as incoming president and chief executive officer as part of a planned leadership transition. Jim will continue to serve as president and chief executive officer until March 31, 2026, when he will transition into the role of

    2/23/26 4:30:00 PM ET
    $SRI
    Auto Parts:O.E.M.
    Consumer Discretionary

    $AAON
    $ACAD
    $ACHC
    $AGM
    SEC Filings

    View All

    SEC Form 10-K filed by Forum Energy Technologies Inc.

    10-K - FORUM ENERGY TECHNOLOGIES, INC. (0001401257) (Filer)

    2/27/26 5:27:18 PM ET
    $FET
    Oil and Gas Field Machinery
    Consumer Discretionary

    SEC Form 10-K filed by Zoom Communications Inc.

    10-K - Zoom Communications, Inc. (0001585521) (Filer)

    2/27/26 5:18:02 PM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 8-K filed by Ambarella Inc.

    8-K - AMBARELLA INC (0001280263) (Filer)

    2/27/26 5:13:15 PM ET
    $AMBA
    Semiconductors
    Technology

    $AAON
    $ACAD
    $ACHC
    $AGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FEMSA Announces Date for Shareholders' Meetings and Dividend Payment Proposal

    MONTERREY, Mexico, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. ("FEMSA" or the "Company") (NYSE:FMX, BMV:FEMSAUBD, FEMSAUB)) announced that it will hold its Annual Ordinary Shareholders' Meeting, as well as an Extraordinary Shareholders' Meeting on March 27, 2026, in Monterrey, Nuevo Leon, Mexico (the "Shareholders' Meetings"). The formal notice will be available in the following link in the coming days: https://femsa.gcs-web.com/shareholder-meeting-information. The detailed proposals for each item on the agenda of the Shareholders' Meetings, as well as the persons nominated to serve as members of FEMSA's Board of Directors and its committees, will be avai

    2/27/26 4:27:10 PM ET
    $FMX
    Beverages (Production/Distribution)
    Consumer Staples

    Global Partners LP Files 2025 Annual Report on Form 10-K

    Global Partners LP (NYSE:GLP) ("Global Partners" or the "Partnership") today announced that its Annual Report on Form 10-K for the year ended December 31, 2025, was filed with the U.S. Securities and Exchange Commission ("SEC") on February 27, 2026. A copy of the Annual Report on Form 10-K is available to be viewed or downloaded from the "SEC Filings" page of the Partnership's investor relations website or from the SEC's website at www.sec.gov. A hard copy of the Partnership's complete audited financial statements also can be obtained free of charge by contacting the Global Partners Investor Relations department at (857) 383-2409 or emailing [email protected]. About Global Partn

    2/27/26 4:05:00 PM ET
    $GLP
    Oil Refining/Marketing
    Energy

    Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

    - Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 -HAMPTON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of CSU, ColdU and SD—

    2/27/26 2:45:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AAON
    $ACAD
    $ACHC
    $AGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Montrose Environmental Group Inc.

    SC 13G - Montrose Environmental Group, Inc. (0001643615) (Subject)

    12/17/24 4:20:32 PM ET
    $MEG
    Professional Services
    Consumer Discretionary

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/13/24 10:39:00 AM ET
    $GRPN
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AAON
    $ACAD
    $ACHC
    $AGM
    Financials

    Live finance-specific insights

    View All

    FEMSA Announces Date for Shareholders' Meetings and Dividend Payment Proposal

    MONTERREY, Mexico, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. ("FEMSA" or the "Company") (NYSE:FMX, BMV:FEMSAUBD, FEMSAUB)) announced that it will hold its Annual Ordinary Shareholders' Meeting, as well as an Extraordinary Shareholders' Meeting on March 27, 2026, in Monterrey, Nuevo Leon, Mexico (the "Shareholders' Meetings"). The formal notice will be available in the following link in the coming days: https://femsa.gcs-web.com/shareholder-meeting-information. The detailed proposals for each item on the agenda of the Shareholders' Meetings, as well as the persons nominated to serve as members of FEMSA's Board of Directors and its committees, will be avai

    2/27/26 4:27:10 PM ET
    $FMX
    Beverages (Production/Distribution)
    Consumer Staples

    Global Partners Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Global Partners LP (NYSE:GLP) ("Global Partners" or the "Partnership") today reported financial results for the fourth quarter and full year ended December 31, 2025. CEO Commentary "We closed 2025 with a fourth quarter that reflected the strength and resilience of our integrated platform," said Eric Slifka, President and Chief Executive Officer. "Built and refined over more than 90 years, our diversified business model and broad network provide a durable competitive advantage, positioning us to navigate market cycles and adapt to dynamic market conditions while meeting the needs of the markets, customers and communities we serve. "The flexibility of our business model was reflected in

    2/27/26 8:00:00 AM ET
    $GLP
    Oil Refining/Marketing
    Energy

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAON
    $ACAD
    $ACHC
    $AGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Partner Global Gp Llc disposed of $11,947,650 worth of Common units representing limited partner interests (247,928 units at $48.19) and acquired $5,776,583 worth of Common units representing limited partner interests (119,871 units at $48.19), decreasing direct ownership by 90% to 24,153 units (SEC Form 4)

    4 - GLOBAL PARTNERS LP (0001323468) (Issuer)

    2/27/26 5:29:23 PM ET
    $GLP
    Oil Refining/Marketing
    Energy

    Chief Financial Officer Hanson Gregory B. was granted 32,618 units of Common units representing limited partner interests and covered exercise/tax liability with 15,770 units of Common units representing limited partner interests, increasing direct ownership by 24% to 87,085 units (SEC Form 4)

    4 - GLOBAL PARTNERS LP (0001323468) (Issuer)

    2/27/26 5:23:18 PM ET
    $GLP
    Oil Refining/Marketing
    Energy

    Chief Operating Officer Romaine Mark was granted 47,210 units of Common units representing limited partner interests and covered exercise/tax liability with 22,826 units of Common units representing limited partner interests, increasing direct ownership by 17% to 169,109 units (SEC Form 4)

    4 - GLOBAL PARTNERS LP (0001323468) (Issuer)

    2/27/26 5:22:14 PM ET
    $GLP
    Oil Refining/Marketing
    Energy